Other applications: √ As a sedative and analgesic (even in intrathecal pain pumps). Sevoflurane is a fluorinated inhalation anesthetic supplied as a liquid and administered as vapor for induction and maintenance of anesthesia. Manufactured in Pennsylvania under the strictest and most up-to-date FDA GMP standards, Sojourn is used annually in over 26 million surgeries worldwide. Its pleasant odor, bronchodilatory effect, and lack of pungency or airway irritation make it an excellent choice for mask induction in both children and adults. Due to its low blood/gas partition coefficient compared to other available inhalation agents, it provides faster induction and recovery. Additionally, its positive effects on organ function have opened new pathways for non-anesthetic applications. Experimental studies have shown lower cytokine and RNA levels in lung tissue, indicating pulmonary protection after edema, with improved oxygenation and lung function. Pilot studies (Zurich) demonstrated that sevoflurane, when used as a sedative instead of intravenous agents during ventilation in COVID-19 patients, may reduce cytokine storm, lung inflammation in ARDS, improve oxygenation, and lower mortality. Its low blood solubility allows rapid alveolar concentration increase during induction and quick decline after discontinuation. In humans, less than 5% is metabolized, with the majority excreted unchanged via the lungs. Metabolized portions are quickly conjugated with glucuronic acid and excreted in urine.

 Indications:
Sevoflurane is used for induction and maintenance of general anesthesia in adults and children, for inpatient or outpatient surgeries.